Overview
What is The Ovarian Cancer Research Fund Inc?
The Ovarian Cancer Research Fund Inc, also known as OCRA, is a New York-based nonprofit organization dedicated to funding medical research, advocating for patients, and providing support and resources to those affected by ovarian cancer. With a mission to promote, advocate, and support scientific research on causes, prevention, diagnosis, treatment, and a cure for ovarian cancer, they have awarded over $113 million in grants to researchers at leading medical centers since 1998. Their investigators work on various fronts, including early detection, genetics, and developing new and better treatments. OCRA researchers have made significant strides in understanding ovarian cancer, such as discovering new therapeutic strategies and identifying biomarkers for monitoring treatment development. They also provide educational resources and support services to individuals and families affected by ovarian cancer. Through the generosity of donors, OCRA continues to make progress in the fight against this deadly disease.
Official website here: www.ocrahope.org
Is The Ovarian Cancer Research Fund Inc legitimate?
The Ovarian Cancer Research Fund Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. The Ovarian Cancer Research Fund Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $540,028
Professional Fundraising Fees: $0
Other Salaries and Wages: $1,678,474
For more financial information, click here
Official website here: www.ocrahope.org
What is the mission statement of The Ovarian Cancer Research Fund Inc?
The Ovarian Cancer Research Fund Inc is dedicated to advocating for and supporting scientific research related to ovarian cancer, with the goal of discovering its causes, prevention, diagnosis, treatment, and ultimately, a cure. The organization provides education about the disease and offers supportive services to those affected by it. Additionally, The Ovarian Cancer Research Fund Inc fosters alliances to further these purposes, acting as a driving force in the fight against ovarian cancer.
Official website here: www.ocrahope.org
Who is the CEO of The Ovarian Cancer Research Fund Inc?
Audra L Moran is the Chair of The Ovarian Cancer Research Fund Inc. The CEO's salary of The Ovarian Cancer Research Fund Inc is $297,983 and their total compensation is $328,635.
Official website here: www.ocrahope.org
What is the revenue of The Ovarian Cancer Research Fund Inc?
The Ovarian Cancer Research Fund Inc's revenue in 2022 was $16,425,940.
Official website here: www.ocrahope.org
Who are the executives of The Ovarian Cancer Research Fund Inc and what are their salaries?
The average compensation at The Ovarian Cancer Research Fund Inc during 2022 was $76,500. There are 29 employees and 2,107 volunteers at The Ovarian Cancer Research Fund Inc.
Here are 32 key members and their salaries (The Ovarian Cancer Research Fund Inc's CEO's salary is $297,983 and their total compensation is $328,635):
- Audra L Moran (President & Ceo)
- Jonathan Zeidman (Chief Development Officer)
- Bibi Ali (Chief Financial Officer)
- Sarah Defeo (Chief Program Officer)
- Debra Levy (Vp - Marketing & Communications)
- Nicole Wargo (Vp - Philanthropic Partnerships & Community Engage)
- Chad Ramsey (Vp - Policy)
- John W Hansbury Esq (Chair) [Trustee/Director]
- Robin S Cohen (Vice President) [Trustee/Director]
- Mark Tessar (Treasurer) [Trustee/Director]
- Dana L Mark Esq (Secretary) [Trustee/Director]
- Jeannette Chang (Director)
- Dr Carmel J Cohen (Director)
- Mei-Li Da Silva Vint Esq (Director)
- Andrew Feuerstein (Director)
- Patricia Goldman (Director)
- Carol J Hamilton (Director)
- Caroline Hirsch (Director)
- Veronica Jordan (Director)
- Edward Labaton Esq (Director)
- Thomas C Liebman (Director)
- Ylain G Mayer (Director)
- Matthew Neal Miller (Director)
- Chris Newcomb (Director)
- John Orrico (Director)
- Lisa Schreiber (Director)
- Elle Simone Scott (Director)
- Christopher Tilberis (Director)
- Mona Baird (Director (1/1-7/5))
- Susan D Bazaar (Director (1/1-11/28))
- Shelley Golden (Director (1/1-12/16))
- Robin Zarel (Director (1/1-6/9))
Official website here: www.ocrahope.org
Where can I find the form 990 for The Ovarian Cancer Research Fund Inc?
The The Ovarian Cancer Research Fund Inc’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.ocrahope.org
Learn more at the official website: www.ocrahope.org
Mission Statement of The Ovarian Cancer Research Fund Inc
The Ovarian Cancer Research Fund Inc, often referred to as OCRA, is a leading organization with a mission to make a significant impact on the fight against ovarian cancer. This nonprofit entity strives to promote, advocate for, and support scientific research related to the causes, prevention, diagnosis, treatment, and ultimately, the cure for ovarian cancer.
By championing research, OCRA aims to expand the understanding of this complex disease and contribute to the development of innovative solutions. Moreover, they provide vital education about ovarian cancer, ensuring that individuals and communities are informed and empowered to take action.
Furthermore, OCRA extends its support to those personally affected by ovarian cancer. Through its various programs and services, the organization offers assistance and resources to help survivors rebuild their lives and navigate their journey. OCRA fosters alliances with other organizations and stakeholders, fostering collaboration and furthering its objectives to create a world where ovarian cancer no longer poses a threat.
Impact
This information is meant to be a general summary of The Ovarian Cancer Research Fund Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
The Ovarian Cancer Research Fund Inc, now known as the Ovarian Cancer Research Alliance (OCRA), has made significant strides in the fight against ovarian cancer. Since its founding in 1994, OCRA has funded groundbreaking medical research, advocated for patients, and provided support and resources to those affected by the disease.
Through their efforts, OCRA has awarded 398 grants for ovarian cancer research to physicians and scientists at leading medical centers, totaling over $113 million in investments. This funding has led to numerous accomplishments, including the discovery of new therapeutic strategies, the identification of genetic markers, and the development of innovative treatment options.
In 2022 alone, OCRA researchers have continued to make progress by studying the impact of aspirin on ovarian cancer, exploring new treatment options through clinical trials, and identifying genetic links between ovarian cancer subtypes and endometriosis. These efforts are crucial in advancing our understanding of ovarian cancer and improving outcomes for patients.
With every dollar donated bringing us closer to a cure, OCRA's impact is undeniable in the fight against this devastating disease. To learn more or join their cause, visit OCRA's website at www.ocrhope.org.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
CONFERENCE
Revenue
$283,846
Organization Details
Founding Year
1994
Phone
(212) 268-1002
Principal Officer
Audra L Moran
Main Address
PO BOX 32141, NEW YORK, NY, 10087
Website
www.ocrahope.org
NTEE Category
Code: T70Z - Philanthropy
If you are a representative of The Ovarian Cancer Research Fund Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.